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S182 Oral Presentationsonly one patient received unrelated PBSC (5  10 6 CD34/kg).
GVHD-prophylaxis comprised Cyclosporine A (CSA) and Myco-
phenolate-Mofetil (MMF). MMF (1200 mg/qm) was administered
until d +100 and tapered thereafter. Two patients received MTX in-
stead of MMF.
Results: The early course after HSCT was uneventful. No acute
GHVD was encountered. No infectious or inflammatory flare
ups were observed. The hematological reconstitution with neutro-
phil (d +19 to +26) and platelet engraftment (d +21 to +22) was in
time. Six to 63 (median 36) months after HSCT, 10 patients are
alive and well (91%) with (95-100%) donor chimerism and stable
hematopoiesis. NBT- and DHR-tests are normalized (95-98%).
All active inflammatory and infectious foci are cured. One adult pa-
tient fathered a child after successful HSCT. One adult patient who
had suffered from severe active therapy-refractory bilateral Asper-
gillosis at transplant and had received a MUD CMV negative
PBSC died at day +150 due to pulmonary failure and endogenous
CMV reactivation.
Conclusion: This modified reduced intensity regimen is efficacious
and well-tolerated in both pediatric and adult high-risk CGD-
patients.72
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Objective: The optimal conditioning regimen for hematopoietic
stem cell transplantation (HSCT) in children with primary immuno-
deficiency diseases is currently unknown. Reduced-intensity condi-
tioning (RIC) concepts allow the inclusion of patients with severe
co-morbidities in transplantation concepts. Here we describe our re-
sults using fludarabine-based RIC regimen for the treatment of pe-
diatric patients with primary immunodeficiency.
Methods: Twenty one patients (8 female, 13 male) with primary
immunodeficiency underwent HSCT using RIC regimen.
Median age at HSCT was 28 months (range: 4 months-14
years).The preparative regimen consisted of fludarabine, melpha-
lan and antithymocyte globulin. 8 patients received stem cell
from healthy full HLA-matched siblings, 7 patients from HLA
matched other relative (four patients from parents, two patients
from grand father and one patient from uncle), 3 patient from
their haploidentical parents and 3 patients from unrelated cord
blood. The graft source was bone marrow in 7 patients, periph-
eral blood stem cells in 11 patients and in 3 patients from cord
blood. The primary immunodeficiencies in these children in-
cluded Leukocyte Adhesion Deficiency type one in 11, Wiskott
Aldrich Syndrome in 3, Griscelli syndrome in 2, Familial Eryth-
rophagocytic Lymphohistiocytosis in 2, severe combined immu-
nodeficiency in 1, Chediak-higashi in 1, and primary CD4
deficiency in 1.For graft-versus-host disease (GVHD) prophy-
laxis, we used Cyclosporine and Methylprednisolone.
Results: All patients except one engrafted. At a median follow-up of
3 months (range, 1-32 months), 18 (85.7%) patients are alive with
sustained engraftment and without recurrent infection, one patient
who not engrafted is alive with uncontrolled disease and two patients
died. 7 patients developed grade II-IV acuteGVHDand 2 developed
limited chronic GVHD.
Among the two dead patients, one of them died from acute
GVHD 30 days after transplantation and the other from aspiration
pneumonia 66 days after transplantation which not related to trans-
plantation. These two dead patients received stem cell from their
haploidentical parents.
Conclusions: These data indicate HSCT following RIC regimen
can be used for treatment of primary immunodeficiency with well
tolerance and low transplant related mortality. When a related hap-
loidentical donor is used, the survival rate is lower than that of pa-
tients receiving HSCT from either an HLA-matched related or
a mismatched HLA-unrelated cords.73
PERFORIN DEPENDENT CYTOTOXICITY REGULATES THE IMMUNE RE-
SPONSE IN TRANS: HOWMUCH DONOR CHIMERISM IS ENOUGH TO PRO-
TECT FROM RECURRENT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
(HLH) AFTER HCT?
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Genetic defects of perforin-dependent cytotoxicity underlie
HLH, a disorder of abnormal immune activation. Allogeneic HCT
can provide a definitive cure for HLH because it corrects these
defects. However, HCT may be complicated by the development
of mixed chimerism after transplantation. There continues to be
significant uncertainty regarding the need for repeat HCT in this
situation. Based on the experience of very limited numbers of
patients, it is thought that relatively small amounts of donor
chimerism are sufficient to protect patients from HLH recurrence
post HCT. We have utilized a murine model of HLH to determine
whether normal cytotoxic function in only a fraction of relevant
hematopoietic or immune cells may restore normal immune
regulation.
Perforin deficient (prf-/-) mice were lethally irradiated and
reconstituted with bone marrow from either wild type (WT),
prf-/-, or other immunodeficient donors. In parallel experiments,
WT or prf-/- T cells were transferred into cyclophosphamide condi-
tioned prf-/- mice. After establishment of bone marrow or T cell
grafts, prf-/- mice were challenged with viral infection and their im-
mune responses were quantitated.
Hematopoietic reconstitution of prf-/- mice with WT bone
marrow reestablished a normal pattern of cytokine production, T
cell activation, and antigen presentation after LCMV infection. As
the fraction of WT chimerism dropped below 10%, however, this
pattern reverted to that seen in prf-/- mice. Complementation
studies demonstrated that though NK cells may play a modest role
in controlling the immune response, reconstitution of normal per-
forin expression in T cells was critical (and sufficient) to reestablish
normal immune regulation. Transfer of purified WT CD8 T cells
alone was also sufficient to reconstitute normal immune responses,
if WT T cell engraftment exceeded 10%.
Because reconstitution of normal perforin expression in a minor
fraction (approximately 10%) of relevant cells is sufficient to reestab-
lish normal immune responsiveness in vivo, we conclude that per-
forin-dependent immunoregulation functions in trans, and that
CD8 T cells are the principle cell population exerting this effect.
These data suggest that donor chimerism of .10% should be suffi-
cient to protect patients from HLH recurrence post HCT, particu-
larly if T cells are of donor origin. These studies also suggest
a minimum target for successful gene therapy of HLH.
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ADOPTIVE IMMUNOTHERAPY AFTER UMBILICAL CORD BLOOD (UCB)
TRANSPLANTATION: MANUFACTURING AND ANALYSIS OF CD19-SPE-
CIFIC UCB-DERIVED T-CELLS FROM SCANT NUMBERS OF UCB MONONU-
CLEAR CELLS
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The rapid procurement, lower risk of graft-versus-host-disease
(GvHD), and the ability to undertake transplantation across
HLA disparities make umbilical cord blood (UCB) an attractive
stem-cell source. Adoptive transfer of tumor-specific T cells after
UCB transplantation (UCBT) is constrained by the functionally
naı¨ve UCB T cells and lack of ability to obtain additional cells.
We have previously shown that the specificity of T cells can be
redirected for CD19 using a chimeric antigen receptor (CAR)
independent of major histocompatibility complex. We have identi-
fied a source of clinical-grade UCB that may be used for
manufacturing without having to reduce the cell dose available
for transplantation. In our laboratory, after UCB units are washed
for clinical infusion, the supernatant is refrozen, and contains small
